Communicable disease threats report, 21-27 January 2018, week 4
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 January 2018 and includes updates on cholera, listeria, influenza, dengue, chikungunya, Zika virus and yellow fever.
Zika virus and safety of substances of human origin – A guide for preparedness activities in Europe
This document includes key elements to be considered in the risk-based decision-making process of mitigating the threats to the safety of substances of human origin posed by Zika virus.
Assessing Seasonal Risks for the Introduction and Mosquito-borne Spread of Zika Virus in Europe
Rocklov, J., Quam, M.B., Sudre, B., German, M., Kraemer, M.U., Brady, O., Bogoch, II, Liu-Helmersson, J., Wilder-Smith, A., Semenza, J.C., Ong, M., Aaslav, K.K., Khan, K.
Zika virus and safety of substances of human origin: a guide for preparedness activities in Europe – first update
This first update of the original guide was prompted by the evolution of the Zika virus epidemic, a new classification system for countries/areas, and recent scientific developments.
Communicable disease threats report, 3-9 March 2019, week 10
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period from 3-9 March 2019 and includes updates on Leishmaniasis and Zika virus disease, Middle East respiratory syndrome coronavirus (MERS-CoV), measles, Ebola virus disease, influenza, Rift Valley fever and mass gathering for Carnival in Brazil.
Questions and answers about Zika virus disease
Questions and answers on Zika virus disease: The disease, Risk for pregnant women, Risk for travellers going to/returning from affected areas, Risk for Zika-infected people to develop Guillain-Barré syndrome, Risk of transmission in Europe
Status, quality and specific needs of Zika virus (ZIKV) diagnostic capacity and capability in National Reference Laboratories for arboviruses in 30 EU/EEA countries, MAY 2016
Mögling, R., Zeller, H., Revez, J., Koopmans, M., Reusken, C., Aberle, S., Van Esbroeck, M., Christova, I., Vilibic-Cavlek, T., Richter, J., Zelena, H., Fomsgaard, A., Jaaskelainen, A.J., Brichler, S., Illiaquer, M., Gonfrier, G., Leparc-Goffart, I., Poveda, J.-D., Hober, D., Fleury, H., Fafi-Kremer, S., Foulongne, V., Henquell, C., Leveque, N., Carles, M.J., Mansuy, J.M., Schmidt-Chanasit, J., Nitsche, A., Papa, A., Mentis, A., Takacs, M., Love, A., Connell, J., Venturi, G., Storoženko, J., Griskevicius, A., Opp, M., Barbara, C., Reusken, C., Reimerink, J., Dudman, S.G., Pancer, K., Alves, M.J., Ceianu, C.S., Ticha, E., Županc, T.A., Sanchez-Seco, M.P., Tolfvenstam, T., Aarons, E.
Zika virus transmission worldwide
Since the epidemic in the Americas peaked in the early spring of 2016, a continuous decline in the number of reported Zika virus disease cases has been observed in the majority of countries throughout the Americas and the Caribbean.